Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$0.24 - $1.11 $1,657 - $7,666
-6,907 Closed
0 $0
Q2 2022

Aug 22, 2022

SELL
$0.41 - $0.91 $548 - $1,217
-1,338 Reduced 16.23%
6,907 $3,000
Q4 2021

Feb 14, 2022

SELL
$1.36 - $2.94 $40,228 - $86,965
-29,580 Reduced 78.2%
8,245 $11,000
Q3 2021

Nov 15, 2021

BUY
$2.97 - $4.84 $35,654 - $58,104
12,005 Added 46.49%
37,825 $114,000
Q2 2021

Aug 12, 2021

BUY
$3.71 - $5.13 $1,087 - $1,503
293 Added 1.15%
25,820 $119,000
Q1 2021

May 17, 2021

SELL
$4.08 - $14.75 $1,097 - $3,967
-269 Reduced 1.04%
25,527 $109,000
Q4 2020

Feb 12, 2021

BUY
$11.06 - $14.01 $7,775 - $9,849
703 Added 2.8%
25,796 $286,000
Q3 2020

Nov 13, 2020

SELL
$10.26 - $14.55 $47,329 - $67,119
-4,613 Reduced 15.53%
25,093 $304,000
Q2 2020

Aug 14, 2020

BUY
$7.11 - $13.76 $8,460 - $16,374
1,190 Added 4.17%
29,706 $409,000
Q1 2020

May 14, 2020

SELL
$5.71 - $15.85 $18,157 - $50,403
-3,180 Reduced 10.03%
28,516 $221,000
Q4 2019

Feb 13, 2020

BUY
$9.6 - $17.75 $26,563 - $49,114
2,767 Added 9.56%
31,696 $484,000
Q3 2019

Nov 13, 2019

BUY
$12.16 - $21.0 $205,808 - $355,425
16,925 Added 140.99%
28,929 $352,000
Q2 2019

Aug 14, 2019

BUY
$9.44 - $19.8 $39,345 - $82,526
4,168 Added 53.19%
12,004 $224,000
Q1 2019

May 15, 2019

BUY
$11.11 - $13.49 $4,599 - $5,584
414 Added 5.58%
7,836 $96,000
Q3 2018

Nov 20, 2018

BUY
$15.53 - $19.97 $7,640 - $9,825
492 Added 7.1%
7,422 $115,000
Q2 2018

Aug 10, 2018

BUY
$15.88 - $19.5 $86,291 - $105,963
5,434 Added 363.24%
6,930 $129,000
Q1 2018

May 17, 2018

SELL
$13.53 - $17.47 $6,995 - $9,031
-517 Reduced 25.68%
1,496 $25,000
Q4 2017

Feb 13, 2018

BUY
$14.41 - $19.15 $29,007 - $38,548
2,013
2,013 $32,000

Others Institutions Holding ATNX

About Athenex, Inc.


  • Ticker ATNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 156,790,000
  • Market Cap $1.57M
  • Description
  • Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar,...
More about ATNX
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.